Article

Transporter-mediated Efflux Influences CNS Side Effects: ABCB1, from Antitarget to Target.

Laboratory for Chemometrics, Department of Chemistry, University of Perugia, Via Elce di Soto 10, 06100 Perugia, Italy.
Molecular informatics 01/2010; 29(1-2):16-26. DOI: 10.1002/minf.200900075
Source: PubMed

ABSTRACT We examined the relationship between sedation and orthostatic hypotension, two central side effects and ABCB1 transporter-mediated efflux for a set of 64 launched drugs that are documented as histamine H1 receptor antagonists. This relationship was placed in the context of passive diffusion (estimated using LogP, the octanol/water partition coefficient), receptor affinity, and the adjusted therapeutic daily dose, in order to account for side effect variability. Within this set, CNS permeability was not dependent on passive diffusion, as no significant differences were found for LogP and its pH-corrected equivalent, LogD(74). Sedation and orthostatic hypotension can be explained within the framework of ABCB1-mediated efflux and adjusted dose, while target potency has less influence. ABCB1, an antitarget for anti-cancer agents, acts in fact as a drug target for non-sedating antihistamines. An empirical set of rules, based on the incidence of these two side-effects, target affinity and dose was used to predict efflux effects for a number of drugs. Among them, azelastine and mizolastine are predicted to be effluxed via ABCB1-mediated transport, whereas aripiprazole, clozapine, cyproheptadine, iloperidone, olanzapine, and ziprasidone are likely to be non-effluxed.

Download full-text

Full-text

Available from: Fabio Broccatelli, Jul 09, 2014
1 Follower
 · 
117 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Assessing CNS penetration in drug discovery and development is important for both CNS projects and non-CNS projects that aim to improve desired or to avoid unwanted central effects of their drug candidates. After a brief reasoning on the flawed old concept of maximising total brain levels, the chapter describes the key principles of the new paradigm of examining CNS penetration and distribution by integrating those parameters and processes that are crucial in controlling unbound brain concentrations as surrogate for the pharmacologically active drug concentration in brain. As a consequence, Kp,uu,brain is about to replace the total brain/plasma ratio Kp,brain as measure of the extent of brain penetration. The chapter outlines strategies, methods and approaches both for the optimisation of CNS penetration as well as for avoiding it, including exemplary lead optimisation screening trees of CNS and non-CNS projects. A comprehensive framework is given linking the pharmacokinetics of a compound in the body’s periphery to its central (unbound) exposure and subsequent PKPD relation in animal models of efficacy, including considerations for the translation of the PKPD relationships from rodents to larger animals and human. The chapter furthermore summarises current knowledge of drug–transporter interactions at the level of the BBB, and outlines the potential of the new concept for refueling the fading interest in CNS drug discovery and development as a result of too many clinical trial failures and an insufficient understanding of the reasons.
    Drug Delivery to the Brain - Physiological Concepts, Methodologies And Approaches, Edited by Margareta Hammarlund-Udenaes, Elizabeth C.M. de Lange, Robert G. Thorne, 01/2014: chapter Integrated Approach to Optimizing CNS Penetration in Drug Discovery: From the Old to the New Paradigm and Assessment of Drug–Transporter Interactions: pages 339-374; AAPS Press, Springer., ISBN: 978-1-4614-9104-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: Optimising drug properties can be an important strategy to limit penetration into the CNS and offers advantages in reducing the risk of undesirable neurological effects When considering the design of these drugs it is important to consider the relative influx and efflux rates at the relevant biological membranes The highest degree of restriction at the brain is probably achievable by utilising active transport to exclude compounds from the brain Affinity for the efflux transporters Pgp and BCRP has been achieved in two in-house chemistry programmes by increasing polar surface area, which resulted in highly orally bioavailable low CNS penetrant compounds in preclinical species.
    Xenobiotica 01/2012; 42(1):11-27. DOI:10.3109/00498254.2011.617847 · 2.10 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Systems pharmacology is an emergent area that studies drug action across multiple scales of complexity, from molecular and cellular to tissue and organism levels. There is a critical need to develop network-based approaches to integrate the growing body of chemical biology knowledge with network biology. Here, we report ChemProt, a disease chemical biology database, which is based on a compilation of multiple chemical-protein annotation resources, as well as disease-associated protein-protein interactions (PPIs). We assembled more than 700,000 unique chemicals with biological annotation for 30,578 proteins. We gathered over 2-million chemical-protein interactions, which were integrated in a quality scored human PPI network of 428,429 interactions. The PPI network layer allows for studying disease and tissue specificity through each protein complex. ChemProt can assist in the in silico evaluation of environmental chemicals, natural products and approved drugs, as well as the selection of new compounds based on their activity profile against most known biological targets, including those related to adverse drug events. Results from the disease chemical biology database associate citalopram, an antidepressant, with osteogenesis imperfect and leukemia and bisphenol A, an endocrine disruptor, with certain types of cancer, respectively. The server can be accessed at http://www.cbs.dtu.dk/services/ChemProt/.
    Nucleic Acids Research 10/2010; 39(Database issue):D367-72. DOI:10.1093/nar/gkq906 · 8.81 Impact Factor